Rex Bionics plc – Proposed Fundraising and Notice of General Meeting

Placing and Subscription to raise £2.1 million and proposed Additional Fundraising to raise approximately £1.0 million and Share Restructuring.

Link here.

12 June 2015 Rex Bionics Plc (AIM: RBX), the pioneer of the REX Robot technology that enhances the mobility of wheelchair users, today announces a proposed Placing and Subscription of 3,500,000 New Ordinary Shares at a price of 60 pence to raise £2.1 million (before expenses).

Highlights

·     3,500,000 new ordinary shares of 10 pence each in the capital of the Company conditionally placed with or subscribed by institutional and other investors to raise proceeds of £2.1 million before expenses

·     Issue price of 60 pence per New Ordinary Share (the “Issue Price”), represents a premium of 6.19  per cent to the mid-market closing price on 11 June 2015

·     Seeking a further £1.0 million through the Additional Fundraising from certain identified investors who will be approached before the General Meeting, potentially issuing up to 1,666,667 additional New Ordinary Shares

·     The net proceeds of the Fundraising will be used to complete the RAPPER II (“Robot-AssistedPhysiotheraPExercises with REX”) clinical trial in which the first patient was recently successfully treated;  initiate a US clinical trial; appoint distribution partners in the United States, China and other markets – and thus over the next 12 months provide a more complete body of clinical and commercial evidence of REX’s significant value creation potential

·     Proposal to sub-divide each Existing Ordinary Share into one Redenominated Ordinary Share of 10 pence and one Deferred Share of 90 pence to reduce the nominal value of each Existing Ordinary Share to facilitate fundraising

·     Stifel is acting as Financial Adviser, Nominated Adviser and sole bookrunner to the Fundraising

·     The Fundraising is conditional, inter alia, on the approval by Shareholders at a general meeting to be held at 10:00 a.m. on 30 June 2015 at the offices of Simmons & Simmons, CityPoint, 1 Ropemaker Street, London EC2Y 9SS (the “General Meeting”) and on the Admission of the New Ordinary Shares to trading on AIM becoming effective.

The Circular to Shareholders, including a notice convening the General Meeting, will be dispatched shortly and will also be available on the Company’s website at www.rexbionics.com

Crispin Simon, Chief Executive of Rex Bionics, commented: “Back in December, we adopted a new plan with five priorities and it is beginning to bear fruit.  We appreciate the support of new and existing investors for our vision – a transformation of the quality of life of wheel chair users.

“These additional funds will allow us to complete our RAPPER II clinical trial and gather further case study evidence on the utility of REX.  We will also launch the product in US and other markets.”

To see a video of Sophie Morgan discussing the benefits of using her REX P, please click here.

For further information please contact:

Rex Bionics Plc

Crispin Simon, Chief Executive Officer

+44 (0) 781 086 6386

Peter Worrall, Chief Financial Officer

+44 (0)1428 645416

Stifel Nicolaus Europe Limited (NOMAD and Broker)

Jonathan Senior/Giles Balleny

+44 (0) 20 7710 7600

Consilium Strategic Communications

Mary-Jane Elliott / Jessica Hodgson / Chris Welsh / Lindsey Neville

rexbionics@consilium-comms.com

+44 (0) 203 709 5700

About Rex Bionics Plc

Rex Bionics (AIM: RXB) is the AIM-listed pioneer of the REX Robot that enhances the mobility of wheelchair users. Founded in Auckland, New Zealand by two robotics engineers with first-hand experience of wheelchair users and their needs, Rex Bionics is working with physiotherapists to develop the practice of Robot-Assisted Physiotherapy (RAP). In a session of RAP, REX lifts patients from a sitting position into a robot-supported standing position, allowing them to take part in a set of supported walking and stretching exercises, designed by specialist physiotherapists.

Wheelchair users are at risk of developing numerous medical complications from extended periods of sitting. By enabling them to spend more time standing, walking and exercising, REX may offer significant health benefits, including improved sleep, cardiovascular performance, maintenance of joint range, and a reduction in common abdominal problems and prescription drug use. A programme of clinical trials is now under way to evaluate these potential benefits.

REX is used by people with complete spinal cord injury, as well as people who have suffered a stroke or other traumatic brain injury; and people with multiple sclerosis and muscular dystrophy. REX P, for use in the home, enables users to walk and stand with their hands free – providing more work and recreation options.

In May 2014, Rex Bionics joined AIM with a fundraising of £10 million (gross) to scale up production, distribution and marketing internationally, in order to support anticipated demand for both REX products as well as developing the next generation of REX devices, REX 3.

The use of REX in the home is not approved in the United States of America.

For more information please visit, www.rexbionics.com

Follow link here for additional details of the Fundraising.